Accessibility Menu
Aroa Biosurgery logo

Aroa Biosurgery(ASX) ARX

Market CapA$203.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-56%
5 Year-46%
1 Year-7%
1 Month-1%
A$0.60
+1.19%
+0.01Today
Aroa Biosurgery last closing stock price
MetricPriceDate
Last closeAUD 0.592026-08-13
Aroa Biosurgery stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.42%AUD 0.572026-08-06
1 month-0.84%AUD 0.602026-07-14
3 month-4.84%AUD 0.622026-05-15
Year to date-20.27%AUD 0.742025-12-31
1 year-7.09%AUD 0.642025-08-13
3 year-33.33%AUD 0.892023-08-14
5 year-45.87%AUD 1.092021-08-13
Since inception-56.3%AUD 1.352020-07-24

Aroa Biosurgery Financials at a Glance

Market Cap

A$203.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$138.03M

Net Income (TTM)

A$6.30M

EPS (TTM)

A$0.01

P/E Ratio

51.30

Dividend

A$0.00

Beta (Volatility)

-0.04 (Low)

Price

A$0.60

Volume

302,511

Open

A$0.60

Previous Close

A$0.59

Daily Range

A$0.59 - A$0.62

52-Week Range

A$0.50 - A$0.80

Estimated Earnings Date

Nov 26, 2026

ARX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aroa Biosurgery

Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories.

Products and Services
  • Endoform Natural and Antimicrobial Restorative Bioscaffold for wound management
  • Myriad Matrix for soft tissue repair and complex wound treatment
  • Reinforced Bioscaffolds for surgical applications in hernia repair
Growth Outlook
  • Revenue increased to AUD 50.82 million in the latest quarter
  • Gross profit margin remains strong at 86.4% for the last quarter
  • Significant cash flow from operations of AUD 5.44 million in Q4 2026
Financial Highlights
  • Net income of AUD 5.15 million reported for Q4 2026
  • Current ratio stands at 4.77, indicating strong liquidity
  • Operating income margin improved to 11.4% in the latest quarter
Aroa Biosurgery Limited is positioned in the healthcare sector, focusing on innovative solutions for wound care and tissue repair. The company's product offerings leverage advanced ECM technology, which is critical for effective healing in both acute and chronic wounds. Recent financial performance indicates a robust growth trajectory, with significant revenue increases and strong profit margins. The liquidity position is favorable, allowing for continued investment in research and development. Overall, Aroa Biosurgery Limited presents a compelling opportunity within the medical devices industry, driven by its innovative product line and solid financial foundation.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Brian Roderick Ward, PhD, MBA

Website

www.aroa.com

Headquarters

Auckland, AU 2022, NZ

ARX Financials

Key Financial Metrics (TTM)

Gross Margin

85.96%

Operating Margin

5.86%

Net Income Margin

4.57%

Return on Equity

7.55%

Return on Capital

4.95%

Return on Assets

6.27%

Earnings Yield

1.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$203.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

345.47M

Volume

302.51K

Avg. Volume

291.87K

Financials (TTM)

Gross Profit

A$118.64M

Operating Income

A$8.08M

EBITDA

A$15.23M

Operating Cash Flow

A$12.96M

Capital Expenditure

-A$1.56M

Free Cash Flow

A$11.41M

Cash & ST Invst.

A$22.60M

Total Debt

A$5.31M

Aroa Biosurgery Performance Analysis

Aroa Biosurgery annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31AUD 57,733,30354.4%
20242024-03-31AUD 64,027,38210.9%
20252025-03-31AUD 77,099,03820.4%
20262026-03-31AUD 92,284,28219.7%
Aroa Biosurgery sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-310.5%
Q22025-09-30N/A
Q32025-12-31-38.1%
Q42026-03-3199.8%
Aroa Biosurgery annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31AUD -0.00-95.7%
20242024-03-31AUD -0.032770.0%
20252025-03-31AUD -0.01-64.8%
20262026-03-31AUD 0.01N/A
Aroa Biosurgery sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31N/A
Q22025-09-30N/A
Q32025-12-31294.3%
Q42026-03-31110.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$50.82M

+146.9%

Gross Profit

A$43.92M

+151.5%

Gross Margin

86.42%

N/A

Market Cap

A$203.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$746.62K

N/A

Employees

273

N/A

Net Income

A$5.15M

+2295.6%

EBITDA

A$8.12M

+386.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$22.60M

+12.9%

Total Debt

A$5.31M

-8.4%

Accounts Receivable

A$33.84M

+6.8%

Inventory

A$5.01M

-32.9%

Long Term Debt

A$4.08M

-14.9%

Short Term Debt

A$1.23M

+21.9%

Return on Assets

6.27%

N/A

Return on Invested Capital

9.29%

N/A

Free Cash Flow

A$4.94M

+601.2%

Operating Cash Flow

A$5.44M

+422.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCC.AXOrthocell Limited
A$0.77-2.53%
DXB.AXDimerix Limited
A$0.30-0.00%
MVF.AXMonash IVF Group Limited
A$0.70-0.43%
AVH.AXAVITA Medical, Inc.
A$2.21-3.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About ARX

What is the current price of Aroa Biosurgery?

Aroa Biosurgery is trading at A$0.60 per share.

What is the 52-week range for Aroa Biosurgery?

Over the past 52 weeks, Aroa Biosurgery has traded between A$0.50 and A$0.80.

How much debt does Aroa Biosurgery have?

As of the most recent reporting period, Aroa Biosurgery reported total debt of A$5.31M.

How much cash does Aroa Biosurgery have on hand?

Aroa Biosurgery reported A$17.54M in cash and cash equivalents in its most recent financial results.

What is Aroa Biosurgery’s dividend yield?

Aroa Biosurgery does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services